Health ❯Healthcare ❯Pharmaceuticals ❯Weight Loss Drugs

Zepbound

Eli Lilly Q2 Revenue Jumps 38%, Lifts 2025 Forecast as Obesity Pill Falls Short

Driven by blockbuster Mounjaro/Zepbound sales, the upgraded guidance omits the effect of anticipated U.S. drug import tariffs

Novo Nordisk Shares Slide 65% From Peak as Analysts Flag 40% Upside

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

Hims & Hers Expands Weight-Loss Offerings with New Medications

Eli Lilly Expands Zepbound Access with New Doses and Lower Prices

FDA Ends Shortage of Eli Lilly’s Weight-Loss Drug, Restricts Copycat Versions

Eli Lilly Partners with Ro to Expand Access to Lower-Cost Zepbound Vials

Eli Lilly Introduces Affordable Zepbound Vials to Address Obesity Drug Shortage

Eli Lilly's Q2 Earnings Surge on High Demand for Weight-Loss Drugs